National Research Ethics Committee

NREC-CT Meeting

12th February 2025

Attendance

Name	Role
Dr Cliona McGovern	Chairperson, NREC-CT B
Dr John Hayden	Deputy Chairperson, NREC CT-B
Ms Serena Bennett	Committee Member, NREC-CT B
Dr Karina Halley	Committee Member, NREC-CT B
Prof. Michaela Higgins	Committee Member, NREC-CT B
Ms Jasmine Joseph	Committee Member, NREC-CT B
Dr Andrew Lindsay	Committee Member, NREC-CT B
Prof. Seamus O'Reilly	Committee Member, NREC-CT B
Ms Evelyn O'Shea	Committee Member, NREC-CT B
Dr Jane Bryant	Project Officer, National Office for RECs
Dr Laura Mackey	Programme Officer, National Office for RECs
Dr Susan Quinn	Programme Manager, National Office for RECs
Dr Peadar Rooney	Project Officer, National Office for RECs
Mr Ciaran Horan	Administrative Assistant, National Office for REC's
Ms Deirdre Ní Fhloinn	Project Officer, National Office for RECs
Ms Rachel McDermott	Administrative Assistant, National Office for REC's
Ms Chita Murray	Programme Manager, National Office for RECs

*Drafted minutes

Apologies: Prof Colm O'Donnell , Ms Ann Twomey, Prof John Wells, Dr Niall McGuinness, Dr Aine De Róiste, Ciaran Lee

Quorum for decisions: Yes

Agenda

- Welcome & Apologies
- 2024-511981-36-00
- 2023-508204-38-00
- 2024-512163-31-00 SM-3
- 2024-511363-28-00 SM-5
- 2022-502442-27-00 SM-3
- 2023-509133-39-00 SM-1
- 2023-506919-18-00 SM-2
- 2023-504993-40-00 SM-3
- 2023-506752-24-00 SM-4
- 2023-510319-20-00 SM-1
- AOB

- The Chair welcomed the NREC-CT B.
  - The minutes from the previous NREC-CT B meeting on 15th January 2025 were approved.
  - The NREC Business Report was discussed and noted.

Applications

2024-511981-36-00

Institutions: Beaumont Hospital

Study title: A Phase 1b/2a Open-label Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) Research Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Participants with AATD Pi*ZZ on WVE-006 (RestorAATion-2)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**
- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. Subject information and informed consent form

- The NREC-CT noted that a new Investigator Brochure (IB) is due March 2025. The NREC requested that as this is a Phase 1b/2a trial with limited safety data, that the sponsor clarify the timeline for when any new safety data will be made available in the PIL for participants. In addition, the NREC seeks clarification whether there are any serious adverse events (SAE's) which should be added to the PIL in advance of the IB update.

- The NREC-CT noted on pg 27 of the Main ICF options to consent to coded samples/data being used for future research, which appear to contradict the statement on pg 5 of the Compliance of Biological Samples Form which refers to samples/data being anonymized for future research. The NREC requests that the Main ICF and Compliance of Biological Samples Form are updated and are aligned. In addition, the Committee requests that if samples/data are to be anonymised, the Main ICF be updated to include a consent statement for the participant to explicitly consent to the processing of their personal data from coded to anonymised data it as per Article 4(2) and (6) General Data Protection Regulation (GDPR).

- The NREC-CT noted that the Future Research ICF provides for two Options of sharing of coded data and samples (pg27). Option 1 covers the Sponsor and collaborators while Option 2 covers non-specified external scientific and research organisations. Option 2 is not described in the Compliance of Biological Samples Form. There is no information provided on where these samples will be stored, how participant rights will be maintained protection including right to request destruction, and who will have access to their samples. The Committee requests that Option 2 on page 27 of the main ICF be removed.

- The NREC-CT noted, that according to the Main PIL (pg 7), the approx. maximum total blood sample volume for a Sentinel participant is 1200 ml, while for all other participants it is 950 ml. However, the total sample volume is reported as 1036.5 ml in the Compliance of Biological Samples Form (pg 1). The Committee requested that the total blood sample is clarified and aligned in all relevant documentation.

- If applicable, the Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment.Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.

- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are

unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.

2023-508204-38-00

Institutions: St James's Hospital

Study title: A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. Recruitment arrangements

- The NREC-CT noted that that the recruitment material does not mention that the trial will be promoted through Cancer Trials Ireland. The Committee requests the Cancer Trials Ireland be listed in the recruitment document if this is the case.

2. Subject information and informed consent form

- The NREC-CT noted that the PIL was 69 pages in length. The Committee requested a summary PIL in addition to the Main PIL to facilitate participants comprehension and thus informed consent.

- The NREC commend the participant information on the investigational agent, and particularly the ophthalmic side effects.

- If applicable, the Sponsor is requested to submit any Part 2 documentation that require updates as a result of the Part 1 Assessment.Please include detail of the Part 1 consideration that triggered the update to the Part 2 documentation.

- The National Office requests that all documentation provided in response to RFI is presented in an accessible and searchable format (Word or original PDF). We are unable to accept scanned documents (including documents modified using Optical Character Recognition) as these documents cannot be optimised for use with assistive software.

2024-512163-31-00 SM-3

Institutions: Wellcome HRB Clinical Research Facility

Study title: ION363-CS1: A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients with Fused in Sarcoma Mutations (FUS-ALS)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. **Subject information and informed consent form**

- The NREC-CT noted that some of the risks in Section 6 of the Main ICF have been redlined (e.g. pulmonary embolism as well as back, buttock and leg pain). The Committee requests that the Sponsor clarify why these have been removed.
- The NREC-CT noted that the Sponsor wishes to submit an updated clean and redacted version of the GP letter. The Committee requests that an updated clean and redacted GP letter be submitted.
- The NREC-CT noted that the full EU-CT number is not listed on the ICF's. The Committee requests that all ICF's are updated to include the full EU-CT number.

2024-511363-28-00 SM-5

Institutions: St Vincent's University Hospital

Study title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-302)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. **Subject information and informed consent form**

- The NREC-CT commends the inclusion and quality of the lay guide summary protocol.

- The NREC-CT noted that higher rates (not quantified) of Candida infections are outlined in the updated protocol (p31), but that the risk ratings remain static in the PIL. The Committee requests clarification on whether the risk ratings for Candida infection in the PIL need to be updated.

2022-502442-27-00 SM-3

Institutions: Connolly Hospital, University Hospital Galway, St Vincent's University Hospital

Study title: A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Favourable

2023-509133-39-00 SM-1

Institutions: St Vincent's University Hospital, Beaumont Hospital, St James's Hospital

Study title: EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. Subject information and informed consent form

- The NREC-CT noted a link to an NHS data protection website on pg 9 of the Main PISCF. The Committee requests the removal of the NHS link and that the text is updated to align with the Irish context.

2023-506919-18-00 SM-2

Institutions: Tallaght University Hospital, Mercy University Hospital, St James's Hospital, St Vincent's University Hospital

Study title: A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. **Subject information and informed consent form**

- The NREC-CT noted that alternate visits between weeks 39 (V8) and 143 (V16) can now be via telephone consultation (TC) rather than in-person according to the Protocol (pg4). This option is not included in the study schedule of assessment in the Main ICF (pg2). The NREC requests clarification on whether this option will be offered to participants in Ireland, and tracked update to the PIL if applicable.
- The NREC-CT noted that 'recordings will be shared with the supplier' on pg 18 of the Main PIL. The Committee requests clarification on which supplier is intended and for the supplier to be named in the PIL.
- The NREC-CT noted that the full 14 digit EU-CT number is not included on the PIL. The Committee requests the PIL is updated to include the 14 digit EU-CT number.

2023-504993-40-00 SM-3

Institutions: Beaumont Hospital, Mater Misericordiae University Hospital

Study title: A Phase 3b, multi-center, randomized, parallel-group, open-label, non-inferiority study evaluating the efficacy, safety, and tolerability of oral dolutegravir/lamivudine once-daily as a first-line regimen compared to oral bictegravir/emtricitabine/tenofovir alafenamide once daily for virologic suppression and maintenance in antiretroviral therapy naive adults living with HIV

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Request for Further Information

- **Additional Information Required RFI**

Part II Considerations

1. **Proof of insurance**

- The NREC-CT noted that the insurance certificate submitted is out of date. The Committee requests that a valid insurance certificate is submitted.

2023-506752-24-00 SM-4

Institutions: St Vincent's University Hospital

Study title: A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Favourable

2023-510319-20-00 SM-1

Institutions: St James's Hospital

Study title: A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in Subjects with HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)

Dossiers Submitted: Part I & II

- **NREC-CT Decision:**

- Favourable

-

- **AOB**: None